IN THIS ISSUE (starts on next page)

In Brief: Ponatinib (Iclusig) Returns ............................................................... p 8
IN BRIEF

Ponatinib (Iclusig) Returns

The October 2013 suspension of marketing and sales of ponatinib (Iclusig – Ariad) for treatment of leukemia¹ has been lifted by the FDA, and the drug is expected to return to the market this month with narrower indications and heightened safety warnings.² The reason for its suspension was a high incidence of thrombotic events, some of them fatal. The new indications limit use of the drug to patients with T315I-positive disease and those “for whom no other tyrosine kinase inhibitor is indicated,” presumably because of resistance or intolerance.
